Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O'Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.

J Clin Oncol. 2010 Jan 1;28(1):69-76. doi: 10.1200/JCO.2009.24.2669. Epub 2009 Nov 23.

2.

Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.

Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A, Öberg KE.

J Clin Endocrinol Metab. 2011 Dec;96(12):3741-9. doi: 10.1210/jc.2011-0666. Epub 2011 Oct 12.

PMID:
21994954
3.

Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, O'Dorisio T, Anthony LB, Hobday T; RADIANT-2 Study Group.

Oncologist. 2013;18(1):46-53. doi: 10.1634/theoncologist.2012-0263. Epub 2012 Dec 21.

4.

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.

Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G, Ricci S, Aieta M, Pucci F, Valente M, Bianco N, Mauri CM, Spada F.

Cancer. 2014 Aug 15;120(16):2457-63. doi: 10.1002/cncr.28726. Epub 2014 Apr 18.

5.

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F.

J Clin Oncol. 2008 Sep 10;26(26):4311-8. doi: 10.1200/JCO.2008.16.7858. Erratum in: J Clin Oncol. 2008 Dec 1;26(34)5660..

6.

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.

Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A, Wolin EM.

Chest. 2013 Apr;143(4):955-62.

PMID:
23187897
8.

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

Kamp K, Gumz B, Feelders RA, Kwekkeboom DJ, Kaltsas G, Costa FP, de Herder WW.

Endocr Relat Cancer. 2013 Oct 14;20(6):825-31. doi: 10.1530/ERC-13-0254. Print 2013 Dec.

9.

Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J.

Endocr Relat Cancer. 2015 Jun;22(3):431-41. doi: 10.1530/ERC-15-0002. Epub 2015 Apr 21.

10.

Real-world study of everolimus in advanced progressive neuroendocrine tumors.

Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G.

Oncologist. 2014 Sep;19(9):966-74. doi: 10.1634/theoncologist.2014-0037. Epub 2014 Aug 12. Erratum in: Oncologist. 2015 May;20(5):570.

11.

Everolimus for advanced pancreatic neuroendocrine tumors.

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.

N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.

12.

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.

Chan JA, Blaszkowsky L, Stuart K, Zhu AX, Allen J, Wadlow R, Ryan DP, Meyerhardt J, Gonzalez M, Regan E, Zheng H, Kulke MH.

Cancer. 2013 Sep 1;119(17):3212-8. doi: 10.1002/cncr.28142. Epub 2013 Jun 3.

13.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.

Lancet. 2011 Dec 10;378(9808):2005-12. doi: 10.1016/S0140-6736(11)61742-X. Epub 2011 Nov 25.

PMID:
22119496
14.

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME.

Endocr Relat Cancer. 2015 Dec;22(6):933-40. doi: 10.1530/ERC-15-0314. Epub 2015 Sep 15.

15.

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.

Anthony LB, Pavel ME, Hainsworth JD, Kvols LK, Segal S, Hörsch D, Van Cutsem E, Öberg K, Yao JC.

Neuroendocrinology. 2015;102(1-2):18-25. doi: 10.1159/000381715. Epub 2015 Mar 21.

PMID:
25824001
16.

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.

Ann Oncol. 2000 Sep;11(9):1127-30.

17.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Epub 2010 Jul 8. Review.

PMID:
20623346
18.

Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.

Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M.

Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18.

PMID:
25454413
19.

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C.

J Clin Oncol. 2015 May 10;33(14):1551-6. doi: 10.1200/JCO.2014.56.2082. Epub 2014 Dec 8.

20.

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.

Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L.

BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184.

Items per page

Supplemental Content

Write to the Help Desk